Clinical Trials Logo

Filter by:
  • Completed  
  • Page [1] ·  Next »
NCT ID: NCT06468579 Completed - Acne Clinical Trials

To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects

Start date: July 25, 2021
Phase: Phase 1
Study type: Interventional

The study is a randomized, double-blind, vehicle-controlled, parallel group, phase 1 study to evaluate the Safety, Tolerability and PK of GT20029 in healthy subjects

NCT ID: NCT06467851 Completed - Chronic Insomnia Clinical Trials

Effect of Suanzaoren Decoction and Huanglian Wendan Decoction on Biorhythm of Insomnia Patients

Start date: August 31, 2023
Phase: N/A
Study type: Interventional

The purpose of this study was to examine the impact of Chinese medicine on melatonin levels in patients with insomnia

NCT ID: NCT06467591 Completed - Stomach Neoplasms Clinical Trials

Prediction Model for Advanced Gastric Cancer in Elderly

Start date: January 1, 2024
Phase:
Study type: Observational

This study aims to develop and validate a Nomogram (mCNS) model for predicting long-term survival in elderly patients following curative resection for advanced gastric cancer. The study is a retrospective multi-center analysis involving 924 gastric cancer patients treated at the Department of Gastrointestinal Surgery of the Affiliated Union Hospital of Fujian Medical University between 2009 and 2013, and 512 patients aged 65 and above who underwent gastric resection at the Affiliated Zhongshan Hospital of Dalian University between 2011 and 2018. An online prognostic tool is introduced to assist clinicians in predicting patient prognosis and customizing treatment and follow-up strategies.

NCT ID: NCT06465264 Completed - Clinical trials for Essential Hypertension

To Assess Allisartan Isoproxil/Amlodipine Tablets in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil

Start date: April 29, 2021
Phase: Phase 3
Study type: Interventional

The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/Amlodipine (240 mg /5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with Amlodipine besylate(5 mg) or Allisartan Isoproxil (240 mg) .

NCT ID: NCT06464874 Completed - Clinical trials for To Compare the Efficacy and Safety of Hybrid ESD and ESD in the Treatment of Colorectal LST

Endoscopic Therapy for Laterally Spreading Tumors (LSTs)

LST
Start date: May 1, 2020
Phase:
Study type: Observational

This study will retrospectively include LST patients who were admitted to 6 medical centers (The Second Affiliated Hospital, College of Medicine, Zhejiang University; The Affiliated Jinhua Hospital, Zhejiang University School of Medicine; First Affiliated Hospital of Huzhou University; The Second Hospital of Jiaxing; Jinhua People's Hospital; Lanxi People's Hospital) from 2020.05.01 to 2023.04.30 with the purpose of comparing the efficacy and safety of hybrid ESD and ESD in the treatment of colorectal LST. The complete resection rate, operation time, operation cost, intraoperative and postoperative complications of hybrid ESD and ESD LST will be compared. To provide strong evidence for the selection of endoscopic treatment strategies for LST.

NCT ID: NCT06464120 Completed - Clinical trials for Performance Enhancing Product Use

Investigating the Post-Activation Performance Enhancement Effects on Skeletal Muscles Under Varied Loading Conditions

Start date: January 2, 2024
Phase: N/A
Study type: Interventional

With the advancement of sports science, Post-Activation Potentiation (PAP) has become a focal point of research, garnering significant attention for its underlying physiological mechanisms. Current studies suggest three primary mechanisms: 1) phosphorylation of myosin regulatory light chains (RLCs); 2) increased recruitment of high-threshold motor units; and 3) a reduction in sarcomere length heterogeneity within muscle fibers due to pre-stimulation (Liu & Li, 2017). These mechanisms collectively contribute to an effect known as Post-Activation Performance Enhancement (PAPE), which significantly enhances muscle strength and explosiveness shortly after activation (Blazevich & Babault, 2019). During the activation process of motor units with increasing loads, low-threshold motor units are recruited first, followed by high-threshold motor units. As the load increases, the root mean square (RMS) value increases linearly, further promoting the overlap of motor unit potentials and the rise in RMS values. This overlap in activation timing among adjacent motor units results in greater overall muscle force output (Liu, 2008; Tian, 2009). The significance of this lies in the fact that as the degree of muscle activation increases, especially under incremental loads, the muscle's ability to adapt to subsequent strength or explosive tasks may be enhanced. In competitive sports, optimizing the relationship between warm-up and performance is crucial. Research indicates that the duration of PAPE varies with individual differences, training type, intensity, and recovery intervals. The characteristics of the PAPE effect also differ. Additionally, following constant loads, the enhancement and decay rates of performance in PAPE show varying rates at different times, and these rates do not exhibit a symmetrical linear change in absolute value (Liang, M 2020; Guo, W et al. 2018; Liu, R and Li, Q. 2017). The competition pace in sports demands precise modulation of performance enhancement rates after activation, and athletes can leverage these characteristics by selecting appropriate loading forms to trigger PAPE at critical moments in competition. To explore the enhancement or decay rates of performance over different time domains, our research team designed a protocol consisting of incremental loads.

NCT ID: NCT06463821 Completed - Clinical trials for Symptom Spectrum and Risk Factors for Fever

Symptom Spectrum and Risk Factors for Fever in Pediatric and Adult Patients With Omicron Infection

Start date: April 8, 2022
Phase:
Study type: Observational

The omicron variant of coronavirus disease 2019 (COVID-19) has caused a global epidemic in 2022. The aim was to investigate the symptom spectrum and risk factors for fever in pediatric and adult patients with omicron infection. From April 8, 2022 to May 17, 2022, this prospective observational study included patients who attended the child-parent sections of the Fangcang shelter hospitals with laboratory-confirmed COVID-19. Patient data were collected from questionnaires. The risk factors for prolonged fever and high fever were identified by univariate and multivariate analyses.

NCT ID: NCT06461598 Completed - Pancreatic Cancer Clinical Trials

Signature for Precise Chemosensitivity Prediction in PDAC

Start date: January 1, 2018
Phase:
Study type: Observational

Pancreatic ductal adenocarcinoma (PDAC) is largely heterogeneous. We sought to develop and validate a signature to precisely predict chemotherapy sensitivity in PDAC. Genetic events of the four most commonly mutated genes in PDAC and expressions of 12 PI3K/AKT/mTOR pathway markers were examined in consecutive patients with PDAC. A 9-feature signature for prediction of chemotherapy benefits was constructed using the LASSO Cox regression model, and validated in two independent cohorts.

NCT ID: NCT06460987 Completed - Safety Issues Clinical Trials

Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy

Start date: December 1, 2022
Phase:
Study type: Observational

IgA nephropathy accounts for about 45 per cent of primary glomerular diseases in China and about 26 per cent of renal biopsies in patients with chronic failure.According to current guideline recommendations, there are limited indications for non-steroidal MRAs. Therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted.

NCT ID: NCT06457269 Completed - Asthma Clinical Trials

Evaluating the Potential of Large Language Models for Respiratory Disease Consultations

EPLLMMRDC
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The clinical trial aimes to evaluate multiple large language models in respiratory disease consultations by comparing their performance to that of human doctors across three major medical consultation scenarios. The main question aims to answer are: - How do large language models perform in comparison to human doctors in diagnosing and consulting on respiratory diseases across various clinical scenarios? In three clinical scenarios including the online query section, the disease diagnosis section and the medical explanation section, research assistants or volunteers will be asked to cross-question all LLMs or real doctors using predefined online questions and their own issues. After each questioning session, a short washout period is implemented to eliminate potential biases.